Literature DB >> 7482105

Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis.

P O-Prasertsawat1, A Bourlert.   

Abstract

BACKGROUND: The introduction of the triazole antifungal agent fluconazole, which can be used via an oral route and single dose, has had a significant impact on patient compliance. GOAL OF THIS STUDY: To compare the efficacy and safety of a single oral dose of 150 mg fluconazole with that of a 100-mg clotrimazole vaginal suppository twice a day in the morning and at bedtime for 3 days in the treatment of vulvovaginal candidiasis. STUDY
DESIGN: A single-blind, randomized controlled trial was conducted at Ramathibodi Hospital between June 1 and September 30, 1993.
RESULTS: There were 53 women in the group treated with fluconazole and 50 in the group treated with clotrimazole. There was no significant difference between the two groups regarding clinical characteristics (age and length of follow-up period). Mycological cure rates approximately 1 week after treatment were 79.2% in the fluconazole group and 80.0% in the clotrimazole group. Approximately 4 weeks after treatment, these rates were 60.4% and 66.0%, respectively. The side effects were minimal and did not warrant any treatment. The differences in the results were not statistically significant.
CONCLUSION: We recommend that a single oral dose of 150 mg of fluconazole be given as an alternative method of treating vulvovaginal candidiasis, but the cost is higher than for clotrimazole.

Entities:  

Keywords:  Asia; Bacterial And Fungal Diseases; Candidiasis; Clinical Research; Comparative Studies; Developing Countries; Diseases; Drugs--administraction and dosage; Infections; Research Methodology; Research Report; Southeastern Asia; Studies; Thailand; Treatment

Mesh:

Substances:

Year:  1995        PMID: 7482105     DOI: 10.1097/00007435-199507000-00005

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  5 in total

1.  Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.

Authors:  R Scott McClelland; Barbra A Richardson; Wisal M Hassan; Vrasha Chohan; Ludo Lavreys; Kishorchandra Mandaliya; James Kiarie; Walter Jaoko; Jeckoniah O Ndinya-Achola; Jared M Baeten; Ann E Kurth; King K Holmes
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

2.  Assessment of Effectiveness of Fluconazole and Clotrimazole in Treating Oral Candidiasis Patients: A Comparative Study.

Authors:  R C Jagat Reddy; S Jeelani; P Duraiselvi; M Kandasamy; G Suresh Kumar; R Azhal Vel Pandian
Journal:  J Int Soc Prev Community Dent       Date:  2017-03-29

3.  Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis.

Authors:  Fen Qin; Quan Wang; Chunlian Zhang; Caiyun Fang; Liping Zhang; Hailin Chen; Mi Zhang; Fei Cheng
Journal:  Infect Drug Resist       Date:  2018-10-17       Impact factor: 4.003

4.  Vulvovaginal candidiasis: A real-world evidence study of the perceived benefits of Canesten®.

Authors:  Lei Zhang; Raffaella De Salvo; Andreas Ehret; Kimberley Young; Sonja Trapp
Journal:  SAGE Open Med       Date:  2022-03-28

5.  Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).

Authors:  Hayley J Denison; Julia Worswick; Christine M Bond; Jeremy M Grimshaw; Alain Mayhew; Shakila Gnani Ramadoss; Clare Robertson; Mary Ellen Schaafsma; Margaret C Watson
Journal:  Cochrane Database Syst Rev       Date:  2020-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.